Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, Cisplatin, and Nab-paclitaxel as Neoadjuvant Therapy for High-risk Resectable Intrahepatic Cholangiocarcinoma
KCT0005554Phase 2Withdrawn
- Sponsor
- Samsung Medical Center
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, cisplatin, paclitaxel in intrahepatic cholangiocarcinoma (ICC), sponsored by Samsung Medical Center. Planned start Aug 2021; status: withdrawn.
02
Drugs
gemcitabinecisplatinpaclitaxel
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on KCT0005554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005554.